Title : Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.

Pub. Date : 2014 Jun

PMID : 24700885






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Our aim was to determine whether treatment with the antianginal agent trimetazidine, which inhibits fatty acid oxidation in the heart secondary to inhibition of 3-ketoacyl-CoA thiolase (3-KAT), may have off-target effects on glycemic control in obesity. Trimetazidine thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 Mus musculus
2 We fed C57BL/6NCrl mice a high-fat diet (HFD) for 10 weeks before a 22-day treatment with the 3-KAT inhibitor trimetazidine (15 mg/kg per day). Trimetazidine thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 Mus musculus